Literature DB >> 8232929

Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy.

Z Simmons1, J W Albers, M B Bromberg, E L Feldman.   

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) may occur in association with a monoclonal gammopathy of undetermined significance (MGUS) or a variety of other systemic illnesses. It is not known if the clinical features of CIDP are altered by the presence of an MGUS. We compared demographic features, clinical presentation, improvement and outcome after initial treatment, and electrodiagnostic features of a group of 77 patients with idiopathic CIDP (CIDP-I, no associated systemic illness) with 26 patients with CIDP in whom an MGUS was found during evaluation of the neuropathy (CIDP-MGUS). Patients with CIDP-MGUS had, on average, a more indolent course and less severe weakness than patients with CIDP-I, despite similar motor conduction studies. CIDP-MGUS patients also demonstrated less functional impairment, more frequent sensory loss, and more abnormal sensory conduction studies than patients with CIDP-I. Because of the greater improvement of CIDP-I patients with treatment, both groups had similar outcomes from their initial episodes of weakness. Subgroup analysis of CIDP-MGUS patients did not demonstrate differences between groups with IgM and IgG or IgA gammopathies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232929     DOI: 10.1212/wnl.43.11.2202

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

1.  Axonal and perikaryal involvement in chronic inflammatory demyelinating polyneuropathy.

Authors:  M Nagamatsu; S Terao; K Misu; M Li; N Hattori; M Ichimura; M Sakai; H Yamamoto; H Watanabe; S Riku; E Ikeda; J Hata; M Oda; M Satake; N Nakamura; S Matsuya; Y Hashizume; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 2.  Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy.

Authors:  David S Saperstein; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

3.  Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.

Authors:  S Kuwabara; S Misawa; M Mori; N Tamura; M Kubota; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

4.  Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins.

Authors:  G Lopate; B J Parks; J M Goldstein; W C Yee; G M Friesenhahn; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

5.  Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Authors:  T Maisonobe; B Chassande; M Vérin; M Jouni; J M Léger; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

6.  Neuro-ophthalmological Complications of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Authors:  S J Hickman; J A Allen; A Baisre; R Batty; H B Lari; O Melen; I M Pepper; P G Sarrigiannis; R E Turbin; S B Wharton; C J McDermott
Journal:  Neuroophthalmology       Date:  2013-07-25

7.  Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J J Figueroa; P J B Dyck; R S Laughlin; J A Mercado; R Massie; P Sandroni; P J Dyck; P A Low
Journal:  Neurology       Date:  2012-02-22       Impact factor: 9.910

Review 8.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 9.  Systematic reviews of treatment for inflammatory demyelinating neuropathy.

Authors:  R A C Hughes
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

10.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.